{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:34:42Z","timestamp":1793943282135,"version":"4.8.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with ulcerative colitis (UC) are at elevated risk of cardiovascular disease vs the general population, despite a lower prevalence of traditional risk factors, including hyperlipidemia. Mechanistic studies in patients with rheumatoid arthritis and psoriasis suggest that tofacitinib restores serum lipids to preinflammation levels by reversing inflammation-induced cholesterol metabolism changes. We reviewed data on lipid levels and cardiovascular events, alongside recommendations for managing lipid levels during tofacitinib treatment in patients with UC, based on up-to-date expert guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were identified from a phase 3\/open-label, long-term extension (OLE) tofacitinib UC clinical program (cutoff May 27, 2019). Literature was identified from PubMed (search terms \u201clipid,\u201d \u201ccholesterol,\u201d \u201clipoprotein,\u201d \u201ccardiovascular,\u201d \u201cinflammation,\u201d \u201catherosclerosis,\u201d \u201ctofacitinib,\u201d \u201crheumatoid arthritis,\u201d \u201cpsoriasis,\u201d \u201cinflammatory bowel disease,\u201d \u201culcerative colitis,\u201d \u201chyperlipidemia,\u201d and \u201cguidelines\u201d) and author knowledge. Data were available from 4 phase 3 clinical trials of 1124 patients with moderately to severely active UC who received\u2005\u22651 dose of tofacitinib 5 or 10 mg twice daily in induction (two identical trials), maintenance, and OLE studies (treatment duration\u2005\u22646.8 years; 2576.4 patient-years of drug exposure).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the OLE study, tofacitinib treatment was not associated with major changes from baseline in total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, total cholesterol\/high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol\/high-density lipoprotein cholesterol, with lipid levels and ratios generally remaining stable over time. The major adverse cardiovascular events incidence rate was 0.26\/100 patient-years (95% confidence interval, 0.11-0.54).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Lipid levels and ratios remained generally unchanged from baseline in the OLE study after tofacitinib treatment, and major adverse cardiovascular events were infrequent. Long-term studies are ongoing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov identifiers<\/jats:title>\n                  <jats:p>NCT01465763, NCT01458951, NCT01458574, NCT01470612<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaa227","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T11:42:16Z","timestamp":1598960536000},"page":"797-808","source":"Crossref","is-referenced-by-count":30,"title":["Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib\u2014Implications for Cardiovascular Risk and Patient Management"],"prefix":"10.1093","volume":"27","author":[{"given":"Bruce E","family":"Sands","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ha","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center , Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[{"name":"PEC2, EA 7460, University of Bourgogne\u2014Franche Comt\u00e9 and Department of Cardiology , CHU Dijon-Bourgogne, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Quirk","sequence":"additional","affiliation":[{"name":"Inflammation & Immunology, Pfizer Inc , Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S","family":"Friedman","sequence":"additional","affiliation":[{"name":"Inflammation & Immunology, Pfizer Inc , Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[{"name":"Inflammation & Immunology, Pfizer Inc , New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Salese","sequence":"additional","affiliation":[{"name":"Inflammation & Immunology, Pfizer Inc , Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[{"name":"Inflammation & Immunology, Pfizer Inc , Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam R","family":"Taub","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California , San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2023112303242206400_CIT0001","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2017-311279","article-title":"Association between chronic immune-mediated inflammatory diseases and cardiovascular risk","volume":"104","author":"Baena-D\u00edez","year":"2018","journal-title":"Heart."},{"key":"2023112303242206400_CIT0002","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut."},{"key":"2023112303242206400_CIT0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.tcm.2015.03.010","article-title":"Inflammatory bowel disease and risk of coronary heart disease","volume":"25","author":"Rungoe","year":"2015","journal-title":"Trends Cardiovasc Med."},{"key":"2023112303242206400_CIT0004","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112303242206400_CIT0005","author":"U.S. Food and Drug Administration"},{"key":"2023112303242206400_CIT0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"2023112303242206400_CIT0007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2023112303242206400_CIT0008","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."},{"key":"2023112303242206400_CIT0009","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2023112303242206400_CIT0010","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol."},{"key":"2023112303242206400_CIT0011","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112303242206400_CIT0012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112303242206400_CIT0013","author":"ClinicalTrials.gov"},{"key":"2023112303242206400_CIT0014","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2023112303242206400_CIT0015","doi-asserted-by":"crossref","first-page":"714","DOI":"10.14309\/00000434-201710001-00714","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study [abstract]","volume":"112","author":"Lichtenstein","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2023112303242206400_CIT0016","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA."},{"key":"2023112303242206400_CIT0017","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation."},{"key":"2023112303242206400_CIT0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"2023112303242206400_CIT0019","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"2023112303242206400_CIT0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet."},{"key":"2023112303242206400_CIT0021","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0022","first-page":"757","article-title":"Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Mill\u00e1n","year":"2009","journal-title":"Vasc Health Risk Manag."},{"key":"2023112303242206400_CIT0023","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"2023112303242206400_CIT0024","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2023112303242206400_CIT0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11745-010-3408-1","article-title":"Atherogenic dyslipidemia: cardiovascular risk and dietary intervention","volume":"45","author":"Musunuru","year":"2010","journal-title":"Lipids."},{"key":"2023112303242206400_CIT0026","article-title":"The role of lipids and lipoproteins in atherosclerosis.","volume-title":"Endotext [Internet]","author":"Linton","year":"2000"},{"key":"2023112303242206400_CIT0027","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat Rev Rheumatol."},{"key":"2023112303242206400_CIT0028","article-title":"The effect of inflammation and infection on lipids and lipoproteins.","volume-title":"Endotext [Internet]","author":"Feingold","year":"2015"},{"key":"2023112303242206400_CIT0029","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1194\/jlr.M200440-JLR200","article-title":"A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers","volume":"44","author":"Hudgins","year":"2003","journal-title":"J Lipid Res."},{"key":"2023112303242206400_CIT0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/annrheumdis-2013-203293","article-title":"Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions","volume":"73","author":"Johnsson","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0031","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0032","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.62.9.842","article-title":"Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis","volume":"62","author":"Boers","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0033","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0049-0172(92)90017-8","article-title":"Dyslipoproteinemia in the course of active rheumatoid arthritis","volume":"22","author":"Lazarevic","year":"1992","journal-title":"Semin Arthritis Rheum."},{"key":"2023112303242206400_CIT0034","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.semarthrit.2008.01.015","article-title":"Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment","volume":"38","author":"Steiner","year":"2009","journal-title":"Semin Arthritis Rheum."},{"key":"2023112303242206400_CIT0035","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0036","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.atherosclerosis.2012.02.032","article-title":"Inflammation modulates human HDL composition and function in vivo","volume":"222","author":"de la Llera Moya","year":"2012","journal-title":"Atherosclerosis"},{"key":"2023112303242206400_CIT0037","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis."},{"key":"2023112303242206400_CIT0038","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023112303242206400_CIT0039","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2036.2008.03886.x","article-title":"Plasma lipids and inflammation in active inflammatory bowel diseases","volume":"29","author":"Romanato","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2023112303242206400_CIT0040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023112303242206400_CIT0041","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"2023112303242206400_CIT0042","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol."},{"key":"2023112303242206400_CIT0043","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Daien","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2023112303242206400_CIT0044","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis","volume":"41","author":"van Sijl","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2023112303242206400_CIT0045","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023112303242206400_CIT0046","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3899\/jrheum.150193","article-title":"Reduction of inflammation drives lipid changes in ankylosing spondylitis","volume":"42","author":"Heslinga","year":"2015","journal-title":"J Rheumatol"},{"key":"2023112303242206400_CIT0047","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023112303242206400_CIT0048","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"2023112303242206400_CIT0049","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"2023112303242206400_CIT0050","author":"European Medicines Agency"},{"key":"2023112303242206400_CIT0051","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"2023112303242206400_CIT0052","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2023112303242206400_CIT0053","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","article-title":"Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability","volume":"47","author":"Koh","year":"2000","journal-title":"Cardiovasc Res"},{"key":"2023112303242206400_CIT0054","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jpeds.2012.03.043","article-title":"Premature subclinical atherosclerosis in pediatric inflammatory bowel disease","volume":"161","author":"Aloi","year":"2012","journal-title":"J Pediatr"},{"key":"2023112303242206400_CIT0055","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.crohns.2013.02.001","article-title":"Endothelial function and cardiovascular risk in active inflammatory bowel diseases","volume":"7","author":"Principi","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2023112303242206400_CIT0056","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijcard.2016.08.141","article-title":"Is activation in inflammatory bowel diseases associated with further impairment of coronary microcirculation?","volume":"223","author":"Caliskan","year":"2016","journal-title":"Int J Cardiol"},{"key":"2023112303242206400_CIT0057","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet."},{"key":"2023112303242206400_CIT0058","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","article-title":"Potential immunomodulatory effects of statins in inflammatory bowel disease","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2023112303242206400_CIT0059","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10620-011-1879-4","article-title":"Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast\/myofibroblast apoptosis in the regeneration\/healing process from TNBS-induced colitis","volume":"57","author":"Abe","year":"2012","journal-title":"Dig Dis Sci."},{"key":"2023112303242206400_CIT0060","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s10620-007-0102-0","article-title":"Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis","volume":"53","author":"Ikeda","year":"2008","journal-title":"Dig Dis Sci"},{"key":"2023112303242206400_CIT0061","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/imm.12662","article-title":"Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis","volume":"149","author":"Lei","year":"2016","journal-title":"Immunology."},{"key":"2023112303242206400_CIT0062","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn\u2019s disease","volume":"155","author":"Grip","year":"2008","journal-title":"Br J Pharmacol."},{"key":"2023112303242206400_CIT0063","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023112303242206400_CIT0064","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2016.02.017","article-title":"Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases","volume":"14","author":"Ananthakrishnan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023112303242206400_CIT0065","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","article-title":"Statins and the risk of colorectal cancer","volume":"352","author":"Poynter","year":"2005","journal-title":"N Engl J Med"},{"key":"2023112303242206400_CIT0066","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.25731","article-title":"Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use","volume":"117","author":"Samadder","year":"2011","journal-title":"Cancer"},{"key":"2023112303242206400_CIT0067","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/ajg.2016.233","article-title":"Statins associated with decreased risk of new onset inflammatory bowel disease","volume":"111","author":"Ungaro","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2023112303242206400_CIT0068","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12664-013-0420-4","article-title":"Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis","volume":"33","author":"Dhamija","year":"2014","journal-title":"Indian J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/6\/797\/53685873\/izaa227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/6\/797\/53685873\/izaa227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:33:08Z","timestamp":1700710388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/6\/797\/5900074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":68,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2021,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa227","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,9,1]]}}}